Background and Aim. To evaluate the effect of @entity6330 and @entity5858 to @entity1534 eradication in different periods of therapeutic protocol. Methods. Infected @entity1 were randomized to one-week tailored triple therapy ( @entity1537 20   mg bid, @entity4581 500   mg bid/ @entity868 400   mg tid if @entity4581 resistant, and @entity115 1000   mg bid) with placebo (group 1, n=100); one week of pretreatment with probiotics (group 2, n=100); and one week of pretreatment with probiotic followed by one week of the same probiotics after treatment (group 3, n=100). Result. PP analysis involved 292 @entity1 , 98 in group 1, 97 in group 2, and 97 in group 3. Successful eradication was observed in 229 @entity1 ; by PP analysis, the eradication rates were significantly higher (P<0.01, 95% CI; 0.71-0.97) in group 2 and group 3 than group 1. ITT analysis eradication rates were significantly higher in group 2 and group 3 than group 1 (P<0.01 95% CI; 0.72-0.87), and there is no significant difference between the three groups (P=0.32) in terms of adverse events. Conclusion. Adding probiotics before or before and after tailored treatment can improve @entity1534 eradication rates. This trial is registered with Thai Clinical Trials Registry number: TCTR20141209001.

Improved XXXX Eradication Rate of Tailored Triple Therapy by Adding Lactobacillus delbrueckii and @entity5858 in Northeast Region of Thailand: A Prospective Randomized Controlled Clinical Trial.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1537 :: ('MESH:D064098', 'Chemical') :: ['esomeprazole'] @entity868 :: ('MESH:D008795', 'Chemical') :: ['metronidazole'] @entity115 :: ('MESH:D000658', 'Chemical') :: ['amoxicillin'] @entity4581 :: ('MESH:D017291', 'Chemical') :: ['clarithromycin'] @entity6330 :: ('1585', 'Species') :: ['Lactobacillus delbrueckii subsp. bulgaricus'] @entity1534 :: ('210', 'Species') :: ['Helicobacter pylori'] @entity5858 :: ('1308', 'Species') :: ['Streptococcus thermophilus']
@entity1534 :: (210,Species) :: ['Helicobacter pylori']
